

In the Claims

Please amend claims 1, 19, and 153, as follows.

1. (currently amended) A pharmaceutical composition comprising:
an isolated peptide-nucleic acid mixed polymer of less than 50 kilodaltons consisting of identical repeating units, each unit having a charge motif composed of a positively charged free amino moiety and a negatively charged moiety, wherein the positively charged free amino moiety of one of the charge motifs is separated by an intervening sequence of at least 32 Å from the positively charged free amino moiety of another charge motif, and wherein the charge motifs are separated by neutral units, and
a pharmaceutically acceptable carrier.

2-18. (canceled)

19. (currently amended) A pharmaceutical composition comprising:
an isolated polypeptide of less than 50 kilodaltons consisting of identical repeating units, each unit having a charge motif composed of a positively charged free amino moiety and a negatively charged moiety, wherein the positively charged free amino moiety and the negatively charged moiety of each charge motif are separated by at least one neutral amino acid, and wherein the positively charged free amino moiety of one of the charge motifs is separated by a distance of at least 8 amino acids from the positively charged amino moiety of another charge motif, and
a pharmaceutically acceptable carrier.

20-152. (canceled)

153. (currently amended) The composition of claim 19, wherein the positively charged free amino moiety and the negatively charged moiety of each charge motif are separated by at least five neutral amino acids.

154. (canceled)

155. (previously presented) The composition of claim 19, wherein the positively charged free amino moiety of one of the charge motifs is separated by a distance of at least 27 amino acids from the positively charged free amino moiety of another charge motif.

156. (previously presented) The composition of claim 19, wherein the positively charged free amino moiety of one of the charge motifs is separated by a distance of at least 37 amino acids from the positively charged free amino moiety of another charge motif.

157. (previously presented) The composition of claim 19, wherein the positively charged free amino moiety of one of the charge motifs is separated by a distance of at least 47 amino acids from the positively charged free amino moiety of another charge motif.

158. (previously presented) The composition of claim 19, wherein the polypeptide is a synthetic polypeptide.

159-160. (canceled)

161. (previously presented) The composition of claim 19, wherein the polypeptide has at least ten modified amino acids.

162-165. (canceled)